Leica launches Bond ChromoPlex II Dual Detection kit
July 2023—Leica Biosystems launched its Bond ChromoPlex II Dual Detection kit for use in immunohistochemistry and chromogenic in situ hybridization on Bond-Max and Bond-III instruments.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
BioMérieux launches BioFire Fireworks software
June 2023—BioMérieux has launched BioFire Fireworks, an integrated software solution for BioFire systems that is part of the company’s Vision Suite data-management product line. Fireworks provides access to a centralized data-management Web portal, giving users insights and analytics into BioFire system performance, utilization, pathogen surveillance, and workflow management. The software was designed, developed, and implemented following industry standards and regulations and gives customers complete control over their data.
Worthington Biochemical product catalog
June 2023—Worthington Biochemical announced that the 23rd edition of its enzyme and biochemical catalog is now available in print and digital formats. The catalog covers a wide array of products for life science applications including immunology, cell biology, molecular biology, research, biochemistry, and bioprocessing. It features Worthington Animal Free enzymes for preclinical, bioprocessing, and biopharma applications produced under ISO 9001–certified and GMP guidelines and contains a number of references, including technical enzyme selection tools, product specifications and application tables, related products at a glance, and product listings by application.
Siemens launches Atellica Hema analyzers
June 2023—Siemens Healthineers launched two solutions for high-volume hematology testing, the Atellica Hema 570 analyzer and Atellica Hema 580 analyzer. Both have a throughput rate of up to 120 tests per hour. The Atellica Hema 570 measures 43 cell parameters and an additional 12 parameters are available on the Hema 580, including immature red blood cell indicators relevant to certain patient populations and an optical-based platelet count that reduces analytical interferences found in other detection technologies. Their user-friendly designs aim to reduce daily maintenance while supporting rapid reagent changes.
SeraCare releases solid tumor CNV reference material
June 2023—LGC SeraCare has developed a comprehensive solid tumor copy number variation reference material in a formalin-fixed, paraffin-embedded format. The Seraseq FFPE Solid Tumor CNV RM includes 12 clinically relevant CNVs associated with solid tumors. Amplifications of these target genes are quantitated by digital PCR, blended in a well-characterized genomic background, and validated with next-generation sequencing. One 10-μm FFPE curl is provided per vial, and the product is designed to give a minimum yield of 100 ng per curl.
ZeptoMetrix introduces Protrol QC material
June 2023—ZeptoMetrix introduced Protrol, a line of products designed to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases. Each lot is supplied with the protein concentration and TCID50 value.
Visiopharm launches Ki-67 algorithm
June 2023—Visiopharm announced the launch of a next-generation Ki-67 algorithm designed to automate the scoring of Ki-67 slides. Tumor nuclei are counted based on their Ki-67 expression and the resulting proliferation index for the whole tumor area is calculated. The algorithm has been cleared under the European Union in vitro diagnostic regulation and is for research use only in the United States.
Momentum Consulting offers plan for lab optimization
June 2023—Momentum Consulting has kicked off its laboratory optimization program for CLIA labs that are emerging from the COVID pandemic with broad or specific needs. The plan covers maximizing existing resources in a laboratory for output in areas such as specimen processing, workflow, new test menus, quality management, billing and collection, sales revenue, and more. Momentum has a team of subject matter experts in these fields to help laboratories improve their productivity.
FDA clears immunoassays to assess risk of preeclampsia
June 2023—Thermo Fisher Scientific announced the FDA has cleared the Thermo Scientific Brahms PlGF Plus Kryptor and Brahms sFlt-1 Kryptor novel biomarkers, both of which received breakthrough designation from the FDA.
Early Lyme disease detection
June 2023—Zeus Scientific has introduced the Zeus Borrelia Modified Two-Tiered Testing (MTTT) algorithm, an FDA-cleared all-ELISA algorithm designed to improve the detection of early Lyme disease by up to 30 percent compared with the standard two-tiered testing algorithm. It replaces a second-tier immunoblot with a second Zeus ELISA methodology to provide additional supportive evidence of infection. The company offers two algorithms: Zeus Borrelia MTTT-1 uses the Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM test system as a first-tier test followed by the Zeus B. burgdorferi IgG/IgM test system; Zeus Borrelia MTTT-2 uses the Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM test system as a first-tier test followed by the Zeus B. burgdorferi IgG test system and Zeus B. burgdorferi IgM test system.